Sidley represented HealthCare Royalty, a leading royalty acquisition company focused on commercial or near-commercial biopharmaceutical products, in its US$250 million non-dilutive note purchase agreement with OPKO Health, Inc. This was secured by OPKO’s profit share payments from Pfizer received pursuant to its license agreement relating to NGENLA™, a once-weekly treatment currently marketed to treat pediatric growth hormone deficiency. The US$250 million note issued under the note purchase agreement bears interest at the 3-month Secured Overnight Financing Rate subject to a 4.0% per annum floor, plus 7.5% per annum. The note has a final maturity date of July 2044, with the first four years requiring interest-only payments The team was led by Asher M. Rubin (Technology and Life Sciences Transactions) and Elizabeth R. Tabas Carson (Global Finance); it included Daniel F. Burkhart, Reid McKinney, and James Blanchard (Global Finance) For additional information, please refer to the press release.~~Sidley represented HealthCare Royalty, a leading royalty acquisition company focused on commercial or near-commercial biopharmaceutical products, in its US$250 million non-dilutive note purchase agreement with OPKO Health, Inc. This was secured by OPKO’s profit share payments from Pfizer received pursuant to its license agreement relating to NGENLA™, a once-weekly treatment currently marketed to treat pediatric growth hormone deficiency. The US$250 million note issued under the note purchase agreement bears interest at the 3-month Secured Overnight Financing Rate subject to a 4.0% per annum floor, plus 7.5% per annum. The note has a final maturity date of July 2044, with the first four years requiring interest-only payments The team was led by Asher M. Rubin (Technology and Life Sciences Transactions) and Elizabeth R. Tabas Carson (Global Finance); it included Daniel F. Burkhart, Reid McKinney, and James Blanchard (Global Finance) For additional information, please refer to the press release.